December 13-14, 2016 | Philadelphia, PA
It’s a wild and crazy time in the drug channel. Get ready for 2017 by joining me at CBI’s 12th Trade and Channel Strategies conference, being held this December in beautiful Philadelphia, PA.
I will kick things off with a keynote address called Drug Channels Update—Things to Watch in 2017. I’ll update everyone on hot topics and identify key strategic issues for the year ahead. As usual, we’ll end the first day with the renowned Trade Throwdown: Battle of the Experts. REMINDER: This is the only CBI event where I present!
CBI’s annual event is one of the industry’s premier events focused on bio/pharma trade, channel, and key account management. Use discount code PKJ933 to save $400.
Read on for more details from CBI. Or just click here to register now. Hope to see you in December!
INFORMATION FROM CBI
CBI’s 12th Annual Trade and Channel Strategies Conference boasts incomparable networking opportunities and unmatched, forward-thinking content from a broad array of stakeholders.
Don’t miss the must-attend event for industry trade, channel, account and pharmacy strategy professionals!
Can’t Miss Keynotes Featuring:
- Adam J. Fein, Ph.D., President, Pembroke Consulting, Inc.; Author, Drug Channels
- William Roth, Founding Partner, Blue Fin Group
Showcasing a dynamic group of key stakeholders from companies including Astellas, AstraZeneca, Bayer Healthcare Pharma, Biogen, BTG International, Depomed, Inc., Goldman Sachs, Pfizer, Purdue Pharma, Takeda, University of Pennsylvania Health System and more!
For more information, please download the complete agenda or visit www.cbinet.com/trade. Drug Channels readers will save $400 off of the standard registration rate when they use discount code PKJ933.*
*Cannot be combined with other offers or used towards a current registration. Cannot be combined with special category rates. Other restrictions may apply.
The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.
No comments:
Post a Comment